---
document_datetime: 2025-11-27 12:01:33
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/uplizna-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: uplizna-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.1632159
conversion_datetime: 2025-12-22 10:39:56.901024
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Uplizna

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| II/0012              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 18/09/2025                          | 10/11/2025                                  | SmPC, Annex II and PL            |                                   |
| PSUSA/10996 /202406  | Periodic Safety Update EU Single assessment - inebilizumab                                                                     | 16/01/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IAIN/0013           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   | 13/01/2025   | 07/03/2025   | Annex II and PL   |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------|
| PSUSA/10996 /202312 | Periodic Safety Update EU Single assessment - inebilizumab                                                                                                                                                                               | 11/07/2024   | n/a          |                   | PRAC Recommendation - maintenance |
| IB/0009             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                      | 08/02/2024   | 21/03/2024   | SmPC              |                                   |
| IB/0008             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                     | 08/02/2024   | n/a          |                   |                                   |
| PSUSA/10996 /202306 | Periodic Safety Update EU Single assessment - inebilizumab                                                                                                                                                                               | 11/01/2024   | n/a          |                   | PRAC Recommendation - maintenance |
| IA/0006             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                  | 02/08/2023   | n/a          |                   |                                   |
| IB/0005             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                   | 07/07/2023   | n/a          |                   |                                   |
| PSUSA/10996 /202212 | Periodic Safety Update EU Single assessment - inebilizumab                                                                                                                                                                               | 06/07/2023   | n/a          |                   | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0004           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   | 19/04/2023   | 21/03/2024   | Annex II and PL        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| PSUSA/10996 /202206 | Periodic Safety Update EU Single assessment - inebilizumab                                                                                                                                                                               | 12/01/2023   | n/a          |                        | PRAC Recommendation - maintenance |
| T/0001              | Transfer of Marketing Authorisation                                                                                                                                                                                                      | 23/05/2022   | 29/06/2022   | SmPC, Labelling and PL |                                   |